Home/Pipeline/Antibodies against tumor-specific carbohydrates (e.g., MUC1)

Antibodies against tumor-specific carbohydrates (e.g., MUC1)

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Panosome

About Panosome

Panosome is a private, pre-clinical stage biotech company leveraging its unique VAST platform to generate antibodies against challenging antigen classes. Spun out from the German Cancer Research Center (DKFZ), the company's core technology utilizes a dense, nanoparticle-forming surface array to elicit potent immune responses. Its initial strategy is to partner with pharmaceutical companies and develop immunotherapeutics in areas like oncology, targeting antigens that have eluded conventional antibody discovery methods.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active